Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia

American Journal of Hematology

Volumn 85, Issue 9, 2010, Pages 655-663

  Auerbach, Michael ^a,b   Silberstein, Peter T ^c   Webb, R Timothy ^d   Averyanova, Svetlana ^e   Ciuleanu, Tudor Eliade ^f   Shao, James ^g   Bridges, Kenneth ^g  

^a Auerbach Hematology Oncology   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^d Genesis Cancer Center   (United States)

^e Nonstate Institution of Health Road Clinical Hospital in Saratov Station   (Russian Federation)

^f THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^g AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

AGED; ANALOGS AND DERIVATIVES; ANEMIA; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; NEOPLASMS; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TIME;

AGED; ANEMIA; DOUBLE-BLIND METHOD; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; INFUSIONS, INTRAVENOUS; IRON; MALE; MIDDLE AGED; NEOPLASMS; TIME FACTORS;

EID: 77956453903     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21779     Document Type: Article

References (27)

1. Amgen Inc., Aranesp (Darbepoetin alfa) Package Insert. Thousand Oaks, CA; 2010.
2. Amgen Inc., Aranesp (Darbepoetin alfa) Summary of Product Characteristics; Thousand Oaks, CA; 2008.
3. Boccia R, Lillie T, Tomita D, et al. The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia. Oncologist 2007;12:584-593.
4. Boccia R, Malik IA, Raja V, et al. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia. Oncologist 2006;11:409-417.
5. Auerbach M, Ballard H. Intravenous iron as standard of care in oncology: Opportunity lost. J Am Pharm Assoc (2003). 2008;48:455-457.
6. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-1220.
7. Auerbach M, Coyne D, Ballard H. Intravenous iron: from anathema to standard of care. Am J Hematol 2008;83:580-588.
8. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of onceweekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-2882.
9. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218-1234.
10. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
11. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-1023.
12. Hotta T, Ogawa H, Saito A, et al. Iron balance following recombinant human erythropoietin therapy for anemia associated with chronic renal failure. Int J Hematol 1991;54:195-200.
13. Ortho Biotech Products, L.P. Procrit (Epoetin alfa) Package Insert, Bridgewater, NJ; 2010.
14. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 2008;111:25-41.
15. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008;26:132-149.
16. NCCN. Clinical Practice Guidelines in Oncology: Chemotherapy-Induced Anemia, Vol. 2; 2009. Available at:http://www.nccn.org/professionals/physician- gls/PDF/anemia.pdf, accessed October 1, 2008.
17. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301-1307.
18. Bastit L, Vandebroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapyinduced anemia. J Clin Oncol 2008;26:1611-1618.
19. Hedenus M, Birgegard G, Nasman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: A randomized multicenter study. Leukemia 2007;21:627-632.
20. Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12: 231-242.
21. Pedrazzoli P, Farris A, Del Prete S, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 2008;26:1619-1625.
22. Auerbach M. Ferumoxytol as a new, safer, easier-to-administer intravenous iron: Yes or no? Am J Kidney Dis 2008;52:826-829.
23. Fishbane S, Ungureanu VD, Maesaka JK, et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996;28:529-534. (Pubitemid 26337591)
24. Beguin Y, Maertens J, De Prijck B, et al. Darbepoetin-alfa and I.V. iron administration after autologous hematopoietic stem cell transplantation: A prospective randomized multicenter trial. ASH Annual Meeting Abstracts 2008;112:54.
25. Cella D, Eton DT, Lai JS, et al. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002;24:547-561.
26. Ford BA, Coyne DW, Eby CS, et al. Variability of ferritin measurements in chronic kidney disease: Implications for iron management. Kidney Int 2009;75:104-110.
27. Henry DH. Supplemental iron: A key to optimizing the response of cancer-related anemia to rHuEPO? Oncologist 1998;3:275-278.